Atypical fibroxanthoma (AFX) is a low-grade skin tumor that looks alarming under the microscope but behaves far less aggressively than its appearance suggests. It is excluded from formal cancer staging systems because it carries little to no risk of spreading to other parts of the body. For most people, surgical removal is curative, and the overall outlook is excellent.
What AFX Looks Like and Where It Appears
AFX typically shows up as a red, dome-shaped nodule on sun-damaged skin, most often on the head or neck of older adults. The surrounding skin usually shows signs of long-term UV exposure, including visible small blood vessels and mottled texture. These tumors tend to grow relatively quickly compared to other skin lesions, which is one reason they can seem concerning at first glance.
Under a microscope, AFX looks genuinely aggressive. The tumor contains large, bizarre-looking cells, spindle-shaped cells, and even multinucleated giant cells. This menacing appearance is precisely why pathologists run a panel of specialized stains to confirm the diagnosis and rule out truly dangerous conditions like melanoma or squamous cell carcinoma. AFX cells test positive for certain markers (CD10 and CD68) while testing negative for markers associated with melanoma, squamous cell carcinoma, and other aggressive tumors. Getting this diagnosis right matters enormously, because the treatment plan and prognosis depend on it.
How Aggressive Is AFX Really?
Despite its dramatic microscopic appearance, AFX behaves as a locally confined tumor. The College of American Pathologists specifically excludes AFX from the soft tissue sarcoma staging system used for more dangerous cancers, categorizing it among tumors that “may recur locally but have either no risk of metastatic disease or an extremely low risk of metastasis.” In practical terms, this means AFX almost never spreads to lymph nodes, lungs, or other organs.
The main concern with AFX is local recurrence, meaning the tumor can regrow in the same spot after removal. How often this happens depends heavily on the surgical technique used. A retrospective study published in JAAD International found that Mohs micrographic surgery, which checks the margins of removed tissue in real time, had a recurrence rate of about 5%. Standard wide local excision, where a margin of surrounding skin is removed but not checked microscopically during the procedure, had a recurrence rate closer to 33% in the same study. All recurrences in that analysis occurred within the first two years after treatment, with an average time to recurrence of 1.6 years.
It’s worth noting that AFX has a more dangerous relative called pleomorphic dermal sarcoma (PDS). PDS looks similar but invades deeper tissues and does carry a meaningful risk of metastasis. When pathologists evaluate an AFX biopsy, one of their key tasks is confirming that the tumor hasn’t invaded beyond the skin’s dermal layer, which would reclassify it as PDS and change the prognosis significantly.
Treatment and What to Expect
Surgery is the standard treatment for AFX, and for most patients it’s the only treatment needed. Mohs surgery is generally preferred when available, particularly for tumors on the head and face where preserving healthy tissue matters and where the lower recurrence rate is a clear advantage. During Mohs surgery, thin layers of tissue are removed and examined one at a time until no tumor cells remain at the edges. This typically happens in a single outpatient visit.
Wide local excision remains an option, especially for tumors in locations where Mohs surgery isn’t practical. The trade-off is a higher chance of the tumor returning locally, which would then require a second procedure. Radiation therapy is occasionally considered for patients who cannot undergo surgery, but it is not the first-line approach.
Follow-Up After Removal
Because recurrences cluster in the first two years, close monitoring during that window is important. A large nationwide study of over 1,100 patients with AFX and related tumors found that clinical follow-up for four years after treatment is sufficient to catch the vast majority of local recurrences. During these visits, your dermatologist will examine the surgical site and surrounding skin. After the four-year mark, the risk of recurrence drops substantially, though routine skin checks remain a good idea given that the same sun damage that caused AFX also raises risk for other skin cancers.
For most people diagnosed with AFX, the combination of accurate pathology, complete surgical removal, and a few years of follow-up visits leads to a straightforward recovery with no further complications.